The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer
Official Title: OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet®) Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer
Study ID: NCT01669239
Brief Summary: This is a prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Hospital Clínic de Barcelona, Barcelona, , Spain
Hospital Universitario Vall d´Hebron, Barcelona, , Spain
Complejo Hospitalario San Pedro de Alcántara, Cáceres, , Spain
Hospital Universitari Arnau de Vilanova de Lleida, Lleida, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Centro Integral Oncológico Clara Campal, Madrid, , Spain
Hospital Universitario Clínico San Carlos, Madrid, , Spain
Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, , Spain
MD Anderson Cancer Center Madrid, Madrid, , Spain
Hospital Universitario Virgen de la Arrixaca, Murcia, , Spain
Hospital Son Llàtzer, Palma de Mallorca, , Spain
Hospital Universitari Son Espases, Palma de Mallorca, , Spain
Hospital Sant Joan de Reus, Reus, , Spain
Hospital Sagrado Corazón USP, Sevilla, , Spain
Hospital Universitario Virgen del Rocío, Sevilla, , Spain
Hospital Virgen de la Macarena, Sevilla, , Spain
Fundación Instituto Valenciano de Oncología, Valencia, , Spain
Hospital Arnau de Vilanova de Valencia, Valencia, , Spain
Hospital Universitario Lozano Blesa, Zaragoza, , Spain
Name: Joaquín Gavilá Gregori, MD
Affiliation: Fundación Instituto Valenciano de Oncología
Role: PRINCIPAL_INVESTIGATOR